- Details
- Description
Packaging Size:
21c/Bottle
Strength:
0.89mg&1.34mg
Composition:
Tivozanib
Treatment:
Renal Cell Carcinoma，RCC
Form:
Capsule
Brand:
LuciTivo
Quantity Unit:
0.89mg*21c/Boxe&1.34mg*21c/Box
Manufacturer:
Lucius Pharmaceuticals (Lao) Co.,Ltd
About Tivozanib
Tivozanib is a medication used for the treatment of advanced renal cell carcinoma (kidney cancer).It is an oral VEGF receptor tyrosine kinase inhibitor.
Renal Cell Carcinoma
Indicated for relapsed or refractory advanced renal cell carcinoma in patients previously treated with ≥2 systemic therapies
1.34 mg PO qDay on Days 1-21 of repeated 28-day cycles
Continue until disease progression or unacceptable toxicity
Dosage Modifications
If dose modifications are required for adverse reactions, reduce to 0.89 mg qDay for 21 days followed by 7 days off treatment
Initiate medical management for diarrhea, nausea, or vomiting prior to dose interruption or reduction
Hypertension
-
Grade 3
- Withhold for persistent Grade 3 despite optimal antihypertensive therapy
- Resume at reduced dose when hypertension controlled at Grade ≤2
-
Grade 4
- Permanently discontinue
Cardiac failure
-
Grade 3
- Withhold until improves to Grade ≤1 or baseline
- Resume at reduced dose or discontinue depending on severity and persistence
-
Grade 4
- Permanently discontinue
Arterial thromboembolic events or reverse posterior leukoencephalopathy syndrome (RPLS)
- Any grade: Permanently discontinue
Hemorrhagic events
- Grade 3 or 4: Permanently discontinue
Proteinuria
-
2 grams or greater proteinuria in 24 hr
- Withhold until less than or equal to 2 grams of proteinuria per 24 hr
- Resume at a reduced dose
- Permanently discontinue for nephrotic syndrome
Other adverse reactions
-
Persistent or intolerable Grade 2 or 3 OR Grade 4 laboratory abnormality
- Withhold until improves to Grade ≤1 or baseline; resume at reduced dose
-
Grade 4
- Permanently discontinue
Renal impairment
- Mild-to-severe (CrCl 15-89 mL/min): No dosage modifications
- End-stage renal disease: Recommend dose not established
Hepatic impairment
- Mild (total bilirubin [TB] ≤1.5x ULN with any AST): No dosage adjustment necessary
- Moderate (TB >1.5 to 3x ULN with any AST): Reduce to 0.89 mg qDay
- Severe (TB 3 to 10x ULN with any AST): Not established
Dosing Considerations
Verify pregnancy in females of reproductive potential before initiation
Related Products
